Allogeneic CD19-OX40-CD3zeta-CAR-mbIL-15-expressing natural killer cells NKX019

{
  "id": "MLC-T-ONC-009846",
  "term": "Allogeneic CD19-OX40-CD3zeta-CAR-mbIL-15-expressing natural killer cells NKX019",
  "field": "Oncology and biomedicine",
  "definition": "A preparation of off-the-shelf (OTS), allogeneic and ex vivo expanded natural killer cells (NKs) that are engineered to express membrane-bound IL-15 (mbIL15) and a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD19 that is coupled to the co-stimulatory domain of OX40 (CD134), and to the zeta chain of the TCR/CD3 complex (CD3-zeta; CD3zeta), with potential immunomodulating and antineoplastic activities. Upon administration of allogeneic CD19-OX40-CD3zeta-CAR-mbIL-15-expressing NK cells NKX019, these cells specifically target and bind to tumor cells expressing CD19. This induces secretion of pro-inflammatory cytokines and results in the lysis of CD19-expressing tumor cells. IL-15 is a pro-survival cytokine that potentiates the immune response against tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.",
  "synonyms": [
    "allogeneic anti-CD-19 CAR NK cells NKX019",
    "allogeneic anti-CD-19 CAR-NKs NKX019",
    "allogeneic CD19-OX40-CD3zeta-CAR-mbIL-15-expressing NK cells NKX019",
    "allogeneic CD19-OX40-CD3zeta-CAR-mbIL-15-expressing NKs NKX019"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/allogeneic-cd19-ox40-cd3zeta-car-mbil-15-expressing-natural-killer-cells-nkx019/"
}